Form 4: Schrodinger Inc. Director Nancy Thornberry Reports Stock and Option Grants

Director Nancy Thornberry reported the grant of restricted stock units and stock options in Schrodinger, Inc.

Summary

• Nancy Thornberry, a director of Schrodinger, Inc. (SDGR), reported changes in beneficial ownership on June 20, 2024.
• On June 18, 2024, Thornberry was granted 5,000 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.
• These RSUs represent a contingent right to receive one share of Schrodinger's common stock each and will vest on the twelve-month anniversary of the grant date or the next annual meeting, subject to continued service.
• Thornberry also received a stock option to buy 8,550 shares of common stock at an exercise price of $19.32 on June 18, 2024.
• This option also vests on the twelve-month anniversary of the grant date or the next annual meeting, subject to continued service.
• Following these transactions, Thornberry beneficially owns 11,250 shares, including 5,000 unvested RSUs, and options to purchase 8,550 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants indicate confidence in the company's future, but it's a routine filing.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted RSUs and stock options.

Industry Context

Equity grants are a common practice in the biotech and software industries to incentivize and retain key personnel. The size and terms of the grants are generally in line with industry standards for companies of Schrodinger's size and stage.

Comparison to Industry Standards

• Companies like Relay Therapeutics and Recursion Pharmaceuticals also utilize stock options and RSUs as part of their compensation packages for directors and executives.
• The vesting schedules, typically one to four years, are consistent with industry norms to ensure long-term commitment.
• The grant sizes are comparable to those of peer companies with similar market capitalizations and growth stages.

Stakeholder Impact

• Shareholders: The grants align director interests with shareholder value.
• Employees: The grants can boost morale by demonstrating confidence in the company's future.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates